Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with deb-TACE in Advanced Hepatocellular Carcinoma
NCT03143270Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in hepatocellular carcinoma (HCC) (3 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of participants with treatment-related adverse events at 12 months. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03143270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143270.